News

Under the deal, BMS will use Halozyme’s Enhanze drug-delivery technology to develop subcutaneously administered immuno-oncology medicines. Enhanze technology is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20),

It is the first biosimilar approved in the US to treat cancer. Mvasi has been approved to treat certain colorectal, brain, lung, kidney and cervical cancers in adult patients. The drug also

As part of the program, Bayer will use Berkeley Lights' Beacon platform to automate biological workflows and gain efficiencies in its drug development process. New biologics are complex

Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City.  The combined company will focus on developing

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) had unanimously voted that the data tabled by GSK supported the efficacy and safety of its shingles candidate

The top-line data from the trial has demonstrated that the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in patient with epidermolysis

Livatag could not improve survival of the HCC patients when compared to best standard of care according to the findings of the phase 3 trial dubbed as ReLive.

Results show that Imfinzi (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in PFS compared to current standard of care with active surveillance in patients with locally-advanced (Stage III),

The funds will support the clinical and regulatory development of ridinilazole for the treatment of CDI, including Summit’s planned Phase 3 development program. Ridinilazole is a highly selective,